Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166434 | 1.00 | ALOX5AP (0.49) | ALOX5APFEN1LMNANPSR1ATM | |
| SCHEMBL13316326 | 1.00 | ALOX5AP (0.49) | ALOX5APFEN1LMNANPSR1ATM | |
| SCHEMBL1429352 | 0.82 | ALDH1A1 (0.51) | ALOX5APFEN1LMNANPSR1F2RL3 | |
| SCHEMBL1429354 | 0.82 | ALDH1A1 (0.51) | ALOX5APFEN1LMNANPSR1F2RL3 | |
| SCHEMBL14045135 | 0.82 | GPR119 (0.49) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL6535537 | 0.82 | GPR119 (0.49) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL25594931 | 0.82 | ALOX5AP (0.47) | ALOX5APFEN1LMNANPSR1F2RL3 | |
| SCHEMBL25594925 | 0.82 | ALOX5AP (0.47) | ALOX5APFEN1LMNANPSR1F2RL3 | |
| SCHEMBL4316198 | 0.80 | FFAR1 (0.49) | ALOX5APFEN1LMNANPSR1GPR119 | |
| SCHEMBL4313801 | 0.80 | FFAR1 (0.49) | ALOX5APFEN1LMNANPSR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | ALOX5AP 3010/4885FEN1 2513/4885LMNA 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.